Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Three germline mutations in the TP53 gene

R S Cornelis1, M van Vliet, M J van de Vijver

  • 1Department of Human Genetics, University of Leiden, The Netherlands.

Human Mutation
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancer.

NPJ breast cancer·2022
Same author

Crossing borders: A systematic review with quantitative analysis of genetic mutations of carcinomas of the biliary tract.

Critical reviews in oncology/hematology·2019
Same author

A specific gene expression signature for visceral organ metastasis in breast cancer.

BMC cancer·2019
Same author

Epithelial-to-mesenchymal transition status of primary breast carcinomas and its correlation with metastatic behavior.

Breast cancer research and treatment·2019
Same author

ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy.

Oncogenesis·2018
Same author

Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis.

Biochimica et biophysica acta. Reviews on cancer·2017
Same journal

RETRACTION: "Differential Effects of AKT1(p.E17K) Expression on Human Mammary Luminal Epithelial and Myoepithelial Cells".

Human mutation·2026
Same journal

Diagnostic Yield of Genome Sequencing in an Iranian Exome-Negative Autosomal-Recessive Intellectual Disability Cohort.

Human mutation·2026
Same journal

Exploring the Functional Impact of Individual <i>DDX41</i> Variants With a Fast and Robust Cell-Based Method.

Human mutation·2026
Same journal

Modeling the Effects of Single Nucleotide Polymorphisms (SNPs) on the Structure and Function of the Human <i>RET</i> Gene: An In Silico Study.

Human mutation·2026
Same journal

Driver Mutation Subtypes Differentially Shape Immune Evasion Landscapes in Melanoma: An AI-Driven Inflammatory Pathway Model Implicating CCNE1.

Human mutation·2026
Same journal

Comment on "When the Outcome Contains the Exposure: Methodological Limits of a Genome-Wide Cross-Trait Analysis of Type 2 Diabetes and MASLD".

Human mutation·2026
See all related articles

This study identifies novel germline mutations in the TP53 tumor-suppressor gene, linked to Li-Fraumeni syndrome and sporadic breast cancers. These findings highlight the diverse roles of TP53 mutations in cancer predisposition and progression.

Area of Science:

  • Genetics
  • Oncology
  • Molecular Biology

Background:

  • The TP53 gene is a critical tumor suppressor involved in maintaining genomic stability.
  • Germline mutations in TP53 are associated with Li-Fraumeni syndrome, a rare inherited cancer predisposition disorder.
  • Understanding TP53 mutations is crucial for cancer risk assessment and therapeutic strategies.

Purpose of the Study:

  • To report novel germline mutations in the TP53 gene.
  • To investigate the association of these mutations with Li-Fraumeni syndrome and sporadic breast cancer.
  • To explore the role of specific TP53 mutations in tumor progression.

Main Methods:

  • Germline DNA sequencing to identify TP53 mutations.
  • Analysis of TP53 mutations in familial cancer cases and sporadic breast tumors.

Related Experiment Videos

  • Genomic analysis of tumor samples to detect additional mutations and loss of heterozygosity.

    • Main Results:

    • Three germline TP53 mutations were identified, two previously unreported.
    • A missense mutation at codon 265 was found in a Li-Fraumeni syndrome family.
    • A constitutional missense mutation at codon 235 and a secondary mutation at codon 245 were identified in a breast cancer patient, with the latter associated with tumor progression.

    Conclusions:

    • Novel germline TP53 mutations contribute to cancer predisposition, including Li-Fraumeni syndrome.
    • Specific TP53 mutations, like the one at codon 245, may play a significant role in tumor progression.
    • There is likely heterogeneity in cancer predisposition potential among different germline TP53 mutations.